Drug Discovery

Research from the MitoCarta Tree of Life project has revealed that mitochondria likely emerged late in the eukaryotic timeline after cells had already developed internal structures. This monumental finding comes from an extensive collaboration involving institutions like the Broad Institute of MIT

Addressing the risk of sarcopenia in patients using GLP-1 therapies has become a primary objective for researchers developing next-generation metabolic interventions. As the global pharmaceutical industry experiences a seismic shift toward metabolic health, the focus has broadened from achieving

Even after adjusting for age and prior therapy lines, metaplastic histology remains a clear indicator of a poor response to the Trop-2-directed antibody-drug conjugate sacituzumab govitecan. This finding, derived from a comprehensive retrospective analysis at the Massachusetts General Hospital

Introduction The landscape of neurological medicine is shifting rapidly as the U.S. Food and Drug Administration accelerates its evaluation of a potential breakthrough that could redefine how patients manage multiple sclerosis. This news centers on fenebrutinib, an investigational oral therapy that

The relentless cycle of invasive eye injections for wet age-related macular degeneration has long remained the heaviest burden for patients who are struggling to preserve their vision. This central challenge defines the current management of retinal diseases, where the high frequency of treatments

Raw material imports for medicine currently account for $749 million in annual spending, representing more than half of the country's total medicinal foreign-exchange costs. This financial burden has catalyzed a strategic pivot toward domestic biotechnology, as the nation seeks to insulate its